A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs PF-06882961 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 06 Jun 2019 Status changed from recruiting to completed.
- 18 Feb 2019 Planned End Date changed from 20 Apr 2019 to 17 Jun 2019.
- 18 Feb 2019 Planned primary completion date changed from 20 Apr 2019 to 17 Jun 2019.